Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Subscription of...

    Subscription of Piramal debentures by Canadian investor approved by CCI

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-11T12:28:10+05:30  |  Updated On 11 Dec 2019 12:28 PM IST

    The Competition Commission of India (CCI) in a tweet said it "approves the subscription of CCDs of Piramal Enterprises by CDPQ. Upon conversion, the equity shareholding of CDPQ in Piramal Enterprises will increase from 3.68 per cent to 8.99 per cent."


    New Delhi: Fair trade regulator CCI on Tuesday said it has given nod to subscription of Piramal Enterprises' compulsory convertible debentures by Canadian institutional investor, Caisse de dépôt et placement du Québec (CDPQ).


    The Competition Commission of India (CCI) in a tweet said it "approves the subscription of CCDs of Piramal Enterprises by CDPQ. Upon conversion, the equity shareholding of CDPQ in Piramal Enterprises will increase from 3.68 per cent to 8.99 per cent."


    Piramal Enterprises in a regulatory filing in October said its board has approved raising of Rs 5,400 crore through a rights issue and preferential allotment of compulsory convertible debentures (CCDs).


    "The rights issue of Rs 3,650 crore at Rs 1,300 per share, is intended to give an opportunity to all its existing shareholders to participate in the capital raise at an attractive price," Piramal Enterprises said in a filing to the BSE.


    "In addition, the company plans to raise Rs 1,750 crore through the preferential allotment of CCDs at a conversion price of Rs 1,510 per share to Canadian institutional investor, Caisse de dépôt et placement du Québec (CDPQ)," Piramal Enterprises had said.


    The preferential allotment will take place by November this year and the rights issue is expected to be completed by February 2020, it had added.


    Read Also: Piramal Pharma, BerGenBio enter partnership for developing leukemia drug Bemcentinib


    These funds will strengthen the company's balance sheet, insulate it against any external shocks and enable it to tap organic and inorganic opportunities arising out of market consolidation across our financial services, pharmaceuticals and information management businesses, Piramal Enterprises Chairman Ajay Piramal had said.


    CDPQ has a long-standing partnership with Piramal Enterprises. It had participated as the anchor investor during its previous capital issuance, investing USD 175 million (around Rs 1,240 crore) out of the total issue size of USD 750 million, (over Rs 5,320 crore).


    Read Also: Piramal Enterprises plans to raise upto Rs 1000 crore via NCDs

    Ajay Piramalbalance sheetcanadian instituteCCICCI approvalcdpqconvertible debenturesdebenturesequityfair trade regulatorPiramalPiramal enterprisessubscriptiontweet
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok